LCAR-M61SQ for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy called LCAR-M61SQ for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has returned or not responded to at least three previous treatments.
- Your cancer is measurable and you have a life expectancy of at least 3 months.
- You have not had a previous treatment targeting GPRC5D.
- You do not have certain other conditions like Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study or for 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
This trial tests a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma that has returned or stopped responding to standard treatments. It aims to see if targeting a specific protein on myeloma cells can help control the disease.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.